Neoplasm Metastasis, Neoplasms
Conditions
Brief summary
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).
Interventions
DRUGLY3022855
Administered IV
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of advanced, refractory breast or prostate cancer that is evaluable by radiologic testing. Participants must have experienced tumor progression on or treatment intolerance to at least one prior therapy and have declined or are ineligible for a standard treatment. * For participants with metastatic castrate-resistant prostate cancer only: * Must continue ongoing androgen deprivation therapy with castrate levels of serum testosterone \<50 nanogram/deciliter (ng/dL) determined within 4 weeks prior to starting treatment * If receiving an antiandrogen as part of first-line hormonal therapy, must have shown progression of disease off the antiandrogen prior to enrollment * Must be willing to continue androgen deprivation therapy while on study, if no prior orchiectomy * Must meet at least 1 of the following 3 criteria for progressive metastatic disease, according to Prostate Cancer Working Group 2 (PCWG2) criteria: * A rise in prostate-specific antigen (minimal value 2 ng/milliliter (mL); ≥3 consecutive rising values) * ≥2 new metastases on transaxial imaging or radionuclide bone scan * Soft tissue progression * Replacement hormone therapy initiated before study entry is permitted * For participants with breast cancer only: * May continue ongoing antiestrogen therapy * Replacement hormone therapy initiated before study entry is permitted * May continue ongoing trastuzumab therapy * Have adequate organ and hematologic function, including: Hepatic: Bilirubin ≤1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN. For participants with tumor involvement of the liver, AST and ALT ≤5.0 × ULN are acceptable. For participants with tumor involvement of the bone, alkaline phosphatase ≤5.0 × ULN is acceptable. Renal: Serum creatinine ≤2.0 × ULN. Absolute neutrophil count (ANC) ≥1.0 × 10\^9/liter (L). Hemoglobin ≥9 grams per deciliter (5.58 millimoles per liter). Platelets ≥90 × 10\^9/L. * Have Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. * Have discontinued all disease-modifying therapy for the primary cancer \>28 days prior to initiation of study treatment. In addition, clinically significant toxicities associated with any prior therapy for the primary cancer, including investigational treatments, have resolved or stabilized to Grade ≤1 toxicity \>28 days prior to initiation of study treatment with the exception of neuropathy, which must have resolved to Grade ≤2. Continuation of a stable dose (minimum of 28 days prior to study entry) of denosumab or bisphosphonate is permitted on study. * Willing and able to comply with study procedures including 1 baseline and 1 posttreatment tumor biopsy procedure. * Male participants: Agree to use a reliable method of birth control and to not donate sperm during the study and for at least 12 weeks following last dose of study drug or country requirements, whichever is longer. * Female participants: Are women of child-bearing potential who test negative for pregnancy within 7 days prior to enrollment based on a urine or serum pregnancy test and agree to use a reliable method of birth control during the study and for 12 weeks following the last dose of the study drug and also must not be breastfeeding, OR are postmenopausal women. * Have an estimated life expectancy that, in the judgment of the investigator, will permit the patient to complete 1 cycle of treatment. * May have received treatment with an investigational product or non-approved use of a drug (other than the study drug used in this study) or device for non-cancer indications; however, not within 28 days prior to the initial dose of study drug.
Exclusion criteria
* Have received treatment within 28 days prior to the initial dose of study drug with an investigational product or non-approved use of a drug or device (other than the study drug/device used in this study) for non-cancer indications or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * Have serious preexisting medical conditions (left to the discretion of the investigator). * Have symptomatic central nervous system (CNS) malignancy or metastasis. * Have an active fungal, bacterial, and/or known viral infection, including human immunodeficiency virus (HIV) or viral (B or C) hepatitis. * Have any of the following cardiovascular conditions: * Symptomatic coronary artery disease currently or within the past 6 months, * Have a second active primary malignancy that, in the judgment of the investigator or sponsor, may affect the interpretation of the results. * Confirmed left ventricular ejection fraction ≤50% or any cardiac insufficiency \> New York Heart Association (NYHA) class II currently or within the past 6 months, * Uncontrolled hypertension (\>170/100 millimeter of mercury \[mm Hg\]) currently or within the past 7 days, or * Serious cardiac arrhythmia (well-controlled atrial fibrillation is permitted) currently or within the past 6 months. * Have a second active primary malignancy that, in the judgment of the investigator or sponsor, may affect the interpretation of the results. * Are unwilling or unable to participate in tumor biopsies. * Have corrected QT interval of \>500 millisecond (msec) on screening electrocardiogram (ECG). * Have received treatment with agents specifically targeting colony stimulating factor 1 (CSF-1) or CSF-1R, including imatinib, nilotinib, and sunitinib.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | Baseline to Day 8 after 1st dose | The immunomodulatory activity of the drug was documented by examining markers that include, but are not limited to: Live-Dead, Cluster of Differentiation 3 (CD3), CD4, CD8, CD14, CD16, Foxhead Box p3 (FoxP3), PD-1, Ki-67, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), Human Leukocyte Antigen-D-relate (HLA-DR), T-cell immunoglobulin and mucin-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and Inducible T-cell COStimulator (ICOS). The expression of these markers was quantified by flow cytometric analysis with an antibody panel. |
| Percentage Change From Baseline in Serum Cytokines | Baseline to Day 8 after 1st dose | The immunomodulatory activity of the drug was measured in participants with advanced, refractory breast or prostate cancers using serum cytokines. Serum cytokine levels was determined by MSD multiplex cytokine immunoassay technology or ELISA, and that may include but not be limited to Interleukin 6 (IL-6), IL-8, IL-10 and Tumor necrosis factor (TNF-α). |
| Serum Cytokine Levels | Day 8 | The immunomodulatory activity of the drug was measured in participants with advanced, refractory breast or prostate cancers using serum cytokines. Serum cytokines will be determined by MSD multiplex cytokine immunoassay or ELISA. The markers to be measured using these technologies include, but are not limited to: CSF-1, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-34, and TNF-α. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855 | 0, 1, 4, 24, 48, 72 and 168 hours post dose on Day 1 and Day 29 | Area under the concentration versus time curve from time zero to tau (τ) of LY3022855 (AUC\[0- τ\]), where tau is dosing interval of (0-14 days). |
| Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | Baseline up to 6 cycles (cycle = 6 weeks) | Disease control rate is the percentage of participants with a confirmed CR, PR or SD, as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. CR is the disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion; SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Disease control rate is calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated, then multiplied by 100. |
Countries
United States
Participant flow
Pre-assignment details
Completers included participants who died from any cause or disease progression and participants who were alive and on study (either on study treatment or in long term follow-up) at study conclusion.
Participants by arm
| Arm | Count |
|---|---|
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer Participants received 1.25 mg/kg of LY3022855 administered IV once every two weeks of a 6-week cycle. | 6 |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer Participants received 1.0 mg/kg of LY3022855 administered IV on weeks 1, 2, 4, and 5 of a 6-week cycle. | 5 |
| LY3022855 - 100 mg Q2W Breast Cancer Participants received 100 mg of LY3022855 administered IV once every two weeks of a 6-week cycle. | 5 |
| LY3022855 - 100 mg QW Breast Cancer Participants received 100 mg of LY3022855 administered IV once weekly of a 6-week cycle. | 6 |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer Participants received 1.25 mg/kg of LY3022855 administered IV once every two weeks of a 6-week cycle. | 8 |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer Participants received 1.0 mg/kg of LY3022855 administered IV on Weeks 1, 2, 4, and 5 of a 6-week cycle. | 4 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Physician Decision | 0 | 0 | 0 | 0 | 2 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 3 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | LY3022855 - 1.25 mg/kg Q2W Breast Cancer | LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | LY3022855 - 100 mg Q2W Breast Cancer | LY3022855 - 100 mg QW Breast Cancer | LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 53.5 Years STANDARD_DEVIATION 16.6 | 55.4 Years STANDARD_DEVIATION 11.8 | 54.8 Years STANDARD_DEVIATION 10.7 | 58.3 Years STANDARD_DEVIATION 16.1 | 69.8 Years STANDARD_DEVIATION 8.3 | 71.0 Years STANDARD_DEVIATION 9.2 | 60.7 Years STANDARD_DEVIATION 13.7 |
| Body Mass Index (BMI) | 27.3 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 6 | 26.5 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 6 | 24.2 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 4.8 | 25.1 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 4.5 | 27.8 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 3.4 | 28.6 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 6.2 | 26.6 Kilogram/Meter^2 (kg/m^2) STANDARD_DEVIATION 4.9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 5 Participants | 5 Participants | 6 Participants | 8 Participants | 4 Participants | 33 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 1 Participants | 5 Participants | 0 Participants | 0 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 4 Participants | 5 Participants | 3 Participants | 0 Participants | 8 Participants | 2 Participants | 22 Participants |
| Region of Enrollment United States | 6 Participants | 5 Participants | 5 Participants | 6 Participants | 8 Participants | 4 Participants | 34 Participants |
| Sex: Female, Male Female | 6 Participants | 5 Participants | 3 Participants | 6 Participants | 0 Participants | 0 Participants | 20 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 8 Participants | 4 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 1 / 5 | 1 / 5 | 1 / 6 | 0 / 8 | 0 / 4 |
| other Total, other adverse events | 6 / 6 | 5 / 5 | 5 / 5 | 6 / 6 | 8 / 8 | 4 / 4 |
| serious Total, serious adverse events | 2 / 6 | 1 / 5 | 1 / 5 | 1 / 6 | 4 / 8 | 0 / 4 |
Outcome results
Primary
Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets
The immunomodulatory activity of the drug was documented by examining markers that include, but are not limited to: Live-Dead, Cluster of Differentiation 3 (CD3), CD4, CD8, CD14, CD16, Foxhead Box p3 (FoxP3), PD-1, Ki-67, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), Human Leukocyte Antigen-D-relate (HLA-DR), T-cell immunoglobulin and mucin-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and Inducible T-cell COStimulator (ICOS). The expression of these markers was quantified by flow cytometric analysis with an antibody panel.
Time frame: Baseline to Day 8 after 1st dose
Population: All enrolled participants who received at least one dose of study drug and have baseline and post baseline data for peripheral blood immune cell subsets.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CD3_% | 1.81 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | C14_HLA_DR_% | -10.31 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD3_% | -4.02 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD4_% | 4.14 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD8_% | 1.53 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD8_% | -27.13 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LIVE_CELL_Count (CNT) | -9.85 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_LIVE_% | -3.54 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD8_% | 35.94 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD8_% | -7.34 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_FOXP3_RATIO | -10.61 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD4_% | 87.25 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD4_% | -36.63 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_CNT | -10.53 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD4_RATIO | -5.53 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD8_% | 3.75 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD14DIM_CD16BR_% | -95.12 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD8_% | 59.83 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD8_% | -14.49 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD4_% | -5.72 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CNT | -7.43 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CNT | -6.41 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD4_% | -17.44 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD4_% | -6.58 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD4_% | 26.31 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CNT | -13.02 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD8_% | 17.47 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD4_RATIO | -7.44 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD8_% | 8.32 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD8_% | 17.18 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD4_% | -29.87 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LIVE_CELL_Count (CNT) | -20.08 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD8_% | -7.17 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD3_% | -4.5 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD8_% | 1.69 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD4_% | 2.39 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD4_% | 18.49 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CNT | 43.43 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD14DIM_CD16BR_% | 12.24 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD4_% | 70.56 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD4_% | 0.77 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_LIVE_% | 16.63 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CNT | 63.34 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_FOXP3_RATIO | -17.56 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD4_% | -18.38 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_CNT | 39.23 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CD3_% | 3.18 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CNT | 29.87 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD8_% | -24.98 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | C14_HLA_DR_% | 5.12 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD4_% | 15.71 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD8_% | 19.43 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD4_RATIO | 0.01 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | C14_HLA_DR_% | -16.39 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_LIVE_% | 20.32 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LIVE_CELL_Count (CNT) | -12.82 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD4_% | -14.6 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_CNT | 1.92 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD8_% | -21.33 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD8_% | -30 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD8_% | -48.43 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD4_% | -30.52 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD4_% | -26.26 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_FOXP3_RATIO | 28.48 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD8_% | -15.46 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD4_% | -15.67 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD4_% | -21.12 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CNT | 4.58 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD8_% | 3.48 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CD3_% | -3.01 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD4_% | -5.25 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD8_% | -2.49 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CNT | -18.38 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD3_% | 1.96 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD4_% | -15.45 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD8_% | 6.18 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CNT | 2.87 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD14DIM_CD16BR_% | -60.59 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD3_% | 28.25 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD8_% | -33.81 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CNT | -51.05 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD4_% | 17.69 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD8_% | -18.81 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD4_% | -6.57 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD8_% | -7.75 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD4_% | 10.35 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD8_% | 69.63 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD4_% | 19.18 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD8_% | 20.59 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD4_% | -21.93 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD8_% | -16.65 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD14DIM_CD16BR_% | -95.09 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | C14_HLA_DR_% | -26.76 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LIVE_CELL_Count (CNT) | 1.23 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_CNT | -19.27 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_LIVE_% | -5.33 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CD3_% | -0.15 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CNT | -18.79 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD4_RATIO | 32.87 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CNT | -9.9 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_FOXP3_RATIO | 123.96 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD4_% | 2.18 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD8_% | -11 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD4_% | -33.46 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD8_% | 9.08 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CD3_% | 0.41 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD14DIM_CD16BR_% | -88.73 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD8_% | 0.7 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CNT | 2.37 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CNT | 11.31 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD4_% | -12.12 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD8_% | -11.85 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD3_% | 0 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD4_% | -13.58 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD4_RATIO | 0.4 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD8_% | 7.87 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD4_% | 40.36 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD8_% | 7.48 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CNT | 13.01 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD8_% | -6.48 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD4_% | 13.51 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_FOXP3_RATIO | -4.12 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD4_% | 0.19 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD4_% | 31.67 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD4_% | 30.4 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD8_% | 20.36 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_CNT | 12.35 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LIVE_CELL_Count (CNT) | 0.43 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_LIVE_% | 8.11 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | C14_HLA_DR_% | -11.77 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD4_% | 17.76 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CNT | -3.16 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CNT | -12.32 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CD3_% | 7.34 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD8_% | -3.75 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD8_% | -33.08 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_LIVE_% | -5.11 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | KI67_CD4_% | 8.18 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | C14_HLA_DR_% | -11.72 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD4_CNT | 4.65 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | TIM3_CD4_% | -18.49 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD8_% | -10.32 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD8_% | -2.2 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_FOXP3_RATIO | -0.64 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD3_CNT | -2.35 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD3_% | -9.91 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | PD1_CD4_% | 4.14 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | ICOS_CD8_% | -25.12 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD8_% | 80.24 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD8_% | 52.01 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | FOXP3_CD4_% | -7.74 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD8_CD4_RATIO | -16.13 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LIVE_CELL_Count (CNT) | -3.48 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | LAG3_CD4_% | 9.74 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CTLA4_CD4_% | 3.59 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets | CD14DIM_CD16BR_% | -92.73 Percent Change |
Primary
Percentage Change From Baseline in Serum Cytokines
The immunomodulatory activity of the drug was measured in participants with advanced, refractory breast or prostate cancers using serum cytokines. Serum cytokine levels was determined by MSD multiplex cytokine immunoassay technology or ELISA, and that may include but not be limited to Interleukin 6 (IL-6), IL-8, IL-10 and Tumor necrosis factor (TNF-α).
Time frame: Baseline to Day 8 after 1st dose
Population: All enrolled participants who received at least one dose of study drug and have baseline and post baseline data for Serum Cytokines.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | TNF-α | -14.51 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-8 | 24.53 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-10 | 83.3 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-6 | 18.13 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-6 | 35.76 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-10 | 12.69 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Serum Cytokines | TNF-α | 48.28 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-8 | 62.84 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-6 | 1956.66 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-8 | 1956.66 Percent Change |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage Change From Baseline in Serum Cytokines | TNF-α | 416.95 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-8 | -19.97 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Serum Cytokines | TNF-α | 3.51 Percent Change |
| LY3022855 - 100 mg QW Breast Cancer | Percentage Change From Baseline in Serum Cytokines | IL-6 | -19.97 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Serum Cytokines | IL-10 | 174.75 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Serum Cytokines | TNF-α | 6.1 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Serum Cytokines | IL-8 | 67.42 Percent Change |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage Change From Baseline in Serum Cytokines | IL-6 | 67.42 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Serum Cytokines | IL-6 | -7.62 Percent Change |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage Change From Baseline in Serum Cytokines | IL-8 | -7.62 Percent Change |
Primary
Serum Cytokine Levels
The immunomodulatory activity of the drug was measured in participants with advanced, refractory breast or prostate cancers using serum cytokines. Serum cytokines will be determined by MSD multiplex cytokine immunoassay or ELISA. The markers to be measured using these technologies include, but are not limited to: CSF-1, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-34, and TNF-α.
Time frame: Day 8
Population: All enrolled participants who received at least one dose of study drug and have baseline and post baseline data for Serum Cytokines.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Serum Cytokine Levels | CSF-1 | 308460 nanograms per liter (ng/L) |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Serum Cytokine Levels | IL-34 | 670.6 nanograms per liter (ng/L) |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Serum Cytokine Levels | CSF-1 | 23564.3 nanograms per liter (ng/L) |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Serum Cytokine Levels | IL-34 | 137.56 nanograms per liter (ng/L) |
| LY3022855 - 100 mg Q2W Breast Cancer | Serum Cytokine Levels | CSF-1 | 290520 nanograms per liter (ng/L) |
| LY3022855 - 100 mg Q2W Breast Cancer | Serum Cytokine Levels | IL-34 | 498.89 nanograms per liter (ng/L) |
| LY3022855 - 100 mg QW Breast Cancer | Serum Cytokine Levels | CSF-1 | 470350 nanograms per liter (ng/L) |
| LY3022855 - 100 mg QW Breast Cancer | Serum Cytokine Levels | IL-34 | 447.11 nanograms per liter (ng/L) |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Serum Cytokine Levels | CSF-1 | 235950 nanograms per liter (ng/L) |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Serum Cytokine Levels | IL-34 | 392.54 nanograms per liter (ng/L) |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Serum Cytokine Levels | CSF-1 | 159550 nanograms per liter (ng/L) |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Serum Cytokine Levels | IL-34 | 123.44 nanograms per liter (ng/L) |
Secondary
Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate)
Disease control rate is the percentage of participants with a confirmed CR, PR or SD, as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. CR is the disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion; SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Disease control rate is calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated, then multiplied by 100.
Time frame: Baseline up to 6 cycles (cycle = 6 weeks)
Population: All enrolled participants who received at least one dose of study drug and have baseline and post-baseline data for disease control rate.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | 50 Percentage of Participants |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | 0 Percentage of Participants |
| LY3022855 - 100 mg Q2W Breast Cancer | Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | 20 Percentage of Participants |
| LY3022855 - 100 mg QW Breast Cancer | Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | 16.7 Percentage of Participants |
| LY3022855 - 1.25 mg/kg Q2W Prostate Cancer | Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | 37.5 Percentage of Participants |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Prostate Cancer | Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate) | 0 Percentage of Participants |
Secondary
Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855
Area under the concentration versus time curve from time zero to tau (τ) of LY3022855 (AUC\[0- τ\]), where tau is dosing interval of (0-14 days).
Time frame: 0, 1, 4, 24, 48, 72 and 168 hours post dose on Day 1 and Day 29
Population: All enrolled participants who received at least one dose of study drug and have evaluable PK data for AUC.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855 | Day 1 | 1950 hours*micrograms/mL | Geometric Coefficient of Variation 35 |
| LY3022855 - 1.25 mg/kg Q2W Breast Cancer | Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855 | Day 29 | 2260 hours*micrograms/mL | Geometric Coefficient of Variation 61 |
| LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer | Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855 | Day 1 | 1030 hours*micrograms/mL | Geometric Coefficient of Variation 38 |
| LY3022855 - 100 mg Q2W Breast Cancer | Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855 | Day 1 | 4310 hours*micrograms/mL | Geometric Coefficient of Variation 14 |
| LY3022855 - 100 mg QW Breast Cancer | Pharmacokinetics (PK): Area Under the Concentration Curve of LY3022855 | Day 1 | 2350 hours*micrograms/mL | Geometric Coefficient of Variation 31 |